Oxatomide in atopic dermatitis;L'oxatomide nel trattamento della dermatite atopica

Minerva Pediatrica

Volumn 50, Issue 7-8, 1998, Pages 359-365

  Duse, M ^a   Merlini, R ^a   Gardenghi, R ^a   Porteri, V ^a  

^a UNIVERSITY OF BRESCIA   (Italy)

Author keywords

Atopic dermatitis; Oxatomide; Paediatry

Indexed keywords

OXATOMIDE;

ARTICLE; ATOPIC DERMATITIS; CHILD; CLINICAL ARTICLE; DRUG EFFICACY; DRUG RESPONSE; DRUG SCREENING; DRUG TOLERABILITY; FEMALE; FOLLOW UP; HUMAN; INFANT; MALE;

ADULT; ANTI-ALLERGIC AGENTS; CHILD; DERMATITIS, ATOPIC; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOOD HYPERSENSITIVITY; HUMANS; INFANT; MALE; PIPERAZINES;

EID: 0032417872     PISSN: 00264946     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Vickers CFH. The natural history of atopic eczema. Acta Derm Venereol (Stockh) 1980;92:113.
2. Schultz Larsen F. The epidemiology of atopic dermatitis. Monogr Allergy 1993;31:9-28.
3. Rystedt I. Prognostic factors in atopic dermatitis. Acta Derm Venereol (Stockh) 1985;65:206.
4. Przybilla B, Eberlein-Konig B, Rueff F. Practical management of atopic eczema. Lancet 1994;343:1342-6.
5. Larsson PA, Liden S. Prevalence of skin diseases among adolescents 12-16 years of age. Acta Derm Venereol (Stockh) 1980;60:415.
6. Larsen FS, Holm NV, Henningsen K. Atopic dermatitis: a genetic-epidemiologic study in a population-based twin sample. J Am Acad Dermatol 1986;15:487.
7. Hanifin JM. Atopic dermatitis. In: Middleton E, Reed CE, Ellis EF, Adkinson NF, Yunginger JW, editors. Allergy. Principles and Practice, 3rd edition. 1988;2:1403-28.
8. Champion RH, Parish WE. Atopic Dermatitis. In: Champion RH, Burton JL, Ebling HJG, editors. Textbook of Dermatology, Fifth edition. 1991;1:589-610.
9. Hathaway MJ, Warner JO. Compliance problems in the dietary management of eczema. Arch Dis Child 1983;58:463.
10. Trzeciakowski JP, Mendelsohn N, Levi R. Antihistamines. In: Middleton E, Reed CE, Ellis EF, Adkinson NF, Yunginger JW, editors. Allergy. Principles and Practice, 3rd edition. 1988;1:715-38.
11. Foreman JC, Pearce FL. Cromolyn. In: Middleton E, Reed CF, Ellis EF, Adkinson NE, Vunginger JW, editors. Allergy. Principles and Practice. 3rd edition. 1988;2:766-81.
12. Benvenuti C, Cavalli E. Farmacovigilanza su oxatomide nel trattamento dell'asma bronchiale allergico. Studio policentrico di confronto tra due schemi posologici su 920 casi. Riv Patol Clin 1993;50(3):167-86.
13. Fischer MJE, Paulussen JJC, Roozendaal R, Tiemessen RC, De Mol NJ, Janssen LHM. Relation between effects ot a set ol anti-allergic drugs on calcium pathways and membrane structure in FcεRI activated signal transduction. Inflamm Res 1996;45:564-73.
14. Fischer MJE, Paulussen JJC, Horbach DA et al. Inhibition of mediator release in RBL-2H3 cells by some H-antagonist derived anti-allergic drugs: relation to lipophilicity and membrane effects. Inflamm Res 1995;44:92-7.
15. Patella V, De Crescenzo G, Marino O, Spadaro G, Genovese A, Marone G. Oxatomide inhibits the release of proinflammatory mediators from human basophils and mast cells. Int Arch Allergy Immunol 1996;111:23-9.
16. Patella V, Marinò I, Spadaro G, Marino O, Fratellanza G, Marone G. Effetto antiinfiammatorio dell'oxatomide sui mastociti polmonari e cutanei e sui basofili umani. G Ital Allergol Immunol Clin 1993;3:203-13.
17. Nijkamp FP, Folkerst G, Beetens JR, De Clerck F. Suppression of PAF-induced bronchoconstriction in the guinea-pig by oxatomide: mechanism of action. Arch Pharmacol 1989;340:111-8.
18. Ciprandi G, Ruffoni S, Scordamaglia A, Canonica GW. Oxatomide treatment of adverse reactions to food (s): clinical study. Folia Allergol Immunol Clin 1987;4(2): 105-7.
19. Ciprandi G, Buscaglia S. Pronxato C. Oxatomide reduces inflammatory events induced by allergen-specific conjunctival challenge. Ann Allergy Asthma Immunol 1995;75(11):446-52.
20. Pozzan M. L'oxatomide nella terapia dell'oculorinite allergica in età pediatrica. Riv Pediatr Prev Soc 1996;46:13-20.
21. Piacentini GL, Peroni DG, Sette L, Bonizzato C. Benedetti M, Boner AL. Inhibition of different dosages of oxatomide or placebo on skin prick test and nasal allergen provocation. J Allergy Clin Immunol 1991;88: 218-25.
22. Bergonz F, Mangili G. Management of atopic dermatitis with a new nipiological formulation (2.5 mg/mL) of oxatomide. II International Days of Allergology and Clinical Immunology. Rome, April 2-5, 1995.
23. Randazzo SD, Emanuele S, Rizza G, Zappalà F, Galota G. L'oxatomide nel trattamento della dermatite atopica. Derm Clin 1985;4:297-302.
24. Fiocchi A, Vimercati E, Arancio R, Sala M, Zuccotti GV. Riva E et al. L'associazione fra dicta e farmaci inibitori del rilascio di mediatori nella terapia delle allergic alimentari in età pediatrica. Studio di confronto fra oxatomide e disodiocromoglicato. Riv Fed Frev Soc Nipiol 1990:40(1):21-6.
25. Miraglia Del Giudice M Jr. Capristo A, Maiello N, Decimo F, Coppola T, Miraglia Del Giudice M sr. Studio in doppia cecità oxatomide versus placebo nel trattamento delle allergopatie alimentari in età pediatrica. 6° Convegno Nazionale Immuno-Allergologia Pediatrica. Saint Vincent, 8 giugno 1990.
26. Emanueli A, Sacchetti G. Post-marketing surveillance methodology as applied in a pharmaceutical medical department. In: Auriche M, Burke J, Duchier J, editors. Securité et Medicaments. Paris: Pergamon Press, 1982:265.
27. o Congrcsso della Società Italiana di Allergologia ed Immunologia Clinica. Milano, 9-12 novembre 1994:490.
28. Ciprandi G, Cipro G, Paolieri F, Venuti D, Canonica GW. Oxatomide does not influence immune response: further support for its use in allergic disorders. Int J Immunotherapy 1987;III(4):301-5.
29. Marini S, Fois D, Fornara R, Moschetta A, Guidetti V. Childhood and adolescence headache: food allergy aspects in a double blind crossover study. In: Gallai V, Guidetti V, editors. Juveline Headache. New York: Elsevier Science Publishers BV, 1991:209-12.